Company intelligence / Profile preview

Immorna

Hangzhou, Zhejiang, Chinaimmorna.com ↗

Ownership: Private
Development stage: Phase 1

Overview

Immorna has received multiple IND clearances from both the US FDA and China NMPA. Its lead program JCXH-211—a self-replicating mRNA encoding IL‑12—has shown excellent safety/tolerability and significant anti-tumor activity in early clinical data. The company also recently dosed its first patient with JCXH‑213, an mRNA-based in vivo CAR therapy. It has received a grant from the Bill & Melinda Gates Foundation to support its RSV vaccine clinical development.[1][4]

Therapeutic areas: OncologyRare DiseasesDermatologyInfectious Diseases
Modalities: mRNA-based therapeutics and vaccinesConventional mRNASelf-replicating RNA (srRNA)Circular RNA
Industry: Biotech

Drug pipeline

13 assets

JCXH-105

12 more assets in the full pipeline.

Request access →

Partnerships

Bill & Melinda Gates Foundation grant for RSV vaccine development[1]

Beyond the preview

Go deeper on Immorna.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Immorna.

Explore the full profile